VC firms back €65m financing for BioSerenity

The round was led by Paris-listed software business Dassault Systemes with participation from existing investors BPI France, Idinvest and LBO France.

The financing comprises €50m series-B equity funding and €15m debt.

The fresh capital will be used to develop BioSerenity's products beyond their initial focus on cardiovascular, neurology and sleep disorders, to grow its business internationally, and to develop new solutions for telemedicine.

Previous funding
Idinvest and Kurma Partners led a €3m seed round for BioSerenity in 2015.

LBO France and BPI France joined Idinvest to provide a €15m series-A in 2017.

Company
Founded in 2014 and headquartered in Paris, BioSerenity develops and sells devices that aim to facilitate the diagnosis and monitoring of patients, as well as calibrate their treatments. The company focuses on four pathological areas: epilepsy, cardiovascular diseases, pregnancy monitoring and sleep disorders.

People
BioSerenity – Pierre-Yves Frouin (president).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• France
• Healthcare
• BPI France
• LBO France
• IDInvest Partners (AGF Private Equity)
• France